Curis is a Lexington, Massachusetts biotechnology company developing emavusertib, an oral drug candidate for blood cancers. It last closed at $0.43 on Nov 20, down 9.03% on the day. The next earnings report for CRIS is expected around Thu, Mar 18, 2027, after the close. For the quarter ended Sep 2026, CRIS reported EPS of -$1.94. Over its last 8 reports the stock moved an average of 5.4% the session after earnings. Over the last 12 months CRIS insiders bought $5K of stock on the open market and sold $0, according to SEC Form 4 filings.
AI Auto Pilots
Is CRIS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CRIS.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on CRISStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
CRIS · as of the Nov 20 close · updated each morning
Downtrend
The stock is 41% below its 20 day and 62% below its 50 day average. It is 1704% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 40). The nearest support is the swing low (Nov 16) at $0.42, and the nearest resistance the Pivot at $0.45.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 38.7%/day
Key levels
$28.4052 week high+6504.7%
$7.71200 day average+1693.0%
$2.02100 day average+369.8%
$0.82Swing high (Oct 8)+90.7%
$0.6950 day average+60.5%
$0.6020 day average+39.5%
$0.47Pivot R1+9.3%
$0.45Pivot+4.7%
$0.43Last close
$0.42Swing low (Nov 16)−2.3%
$0.40Pivot S1−7.0%
$0.3352 week low−23.3%
Indicators
RSI (14)
40.41
Middle of its range
Neutral
MACD
-0.07
Below its signal line
Bearish
Stochastic
7.4
Near the bottom of its range
Oversold
ADX (14)
30.0
Trending up
Williams %R
-99.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-71.3
Oversold below −100, overbought above 100
Neutral
Rate of change
−52.9%
Change over 10 sessions
Bearish
ATR (14)
$0.17
Typical daily range, 38.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 282.1%/day
Key levels
$28.4052 week high+6504.7%
$7.71200 day average+1693.0%
$2.02100 day average+369.8%
$0.82Swing high (Oct 8)+90.7%
$0.6950 day average+60.5%
$0.6020 day average+39.5%
$0.47Pivot R1+9.3%
$0.45Pivot+4.7%
$0.43Last close
$0.42Swing low (Nov 16)−2.3%
$0.40Pivot S1−7.0%
$0.3352 week low−23.3%
Indicators
RSI (14)
23.54
Oversold below 30
Oversold
MACD
-2.88
Above its signal line
Bullish
Stochastic
6.8
Near the bottom of its range
Oversold
ADX (14)
34.6
Trending down
Williams %R
-94.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-66.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−62.2%
Change over 10 sessions
Bearish
ATR (14)
$1.20
Typical daily range, 282.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CRIS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CRIS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow CRIS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for CRISHow many large options trades hit CRIS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in CRIS in the last 90 days.
From SEC Form 4 filings by CRIS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRIS is in one of them and how their past CRIS trades turned out.
Curis is a biotechnology company based in Lexington, Massachusetts, that is developing emavusertib, an oral small molecule drug candidate for blood cancers. The drug is designed to block two cell signaling proteins, IRAK4 and FLT3, which help certain leukemias and lymphomas grow and survive. Curis is testing emavusertib in clinical studies for patients with relapsed or refractory primary central nervous system lymphoma and for patients with chronic lymphocytic leukemia, both in combination with other cancer drugs. The company does not yet have an approved product for sale, so its patients are those enrolled in its clinical trials.